1. Pink Sheet

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

 
• By Brenda Sandburg

Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.

Gavel

Finding that Amgen Inc. has suffered irreparable harm from Sanofi and Regeneron Pharmaceuticals Inc.’s marketing of Praluent (alirocumab), a competitor to Amgen’s PCSK9 inhibitor Repatha (evolocumab), and that monetary damages are inadequate, a district court judge issued a permanent injunction to block US sales of Praluent.

However, in her Jan. 5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet